ESMO 2017 Press Release: LORELEI: Taselisib Boosts Breast Tumor Shrinkage

Excerpt:

“Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor positive and HER2-negative (ER+/HER2-) according to results of the LORELEI trial, presented at the ESMO 2017 Congress in Madrid.

” ‘We were able to detect a reduction in tumor size after only 16 weeks of treatment, compared to patients who received letrozole plus placebo,’ said study investigator Dr. Cristina Saura, from Vall d’Hebron University Hospital in Barcelona, Spain. ‘Any decrease in tumor measurements is something positive for patients because this means the drug has had activity against their tumor in a short period of time.’ ”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Survival Compared for Treatments of Uncommon Eye Cancer

“In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events.”

Editor’s note: Selumetinib is a targeted drug that may benefit people with ocular melanoma. In a recent clinical trial to test the drug in volunteer patients, selumetinib was compared to standard chemotherapy. More patients treated with selumetinib experienced tumor shrinkage than those treated with chemotherapy, and patients treated with selumetinib experienced a longer lag time (about 4 months, compared to 2 months) before their cancer progressed. However, there was no difference in overall survival between patients treated with selumetinib and patients treated with standard chemotherapy. Unfortunately, almost all of the patients who took selumetinib experienced adverse side effects.


Experimental Drug Shows Early Promise for Some Cases of Advanced Melanoma

“An experimental cancer drug that activates the immune system has shown early promise for advanced cases of melanoma skin cancer, researchers report.

“The findings come from an early stage trial of just 31 patients. But experts were cautiously optimistic about what the study showed: The drug’s side effects were manageable, and four patients saw their tumors shrink.

“That’s a small number, but a trial like this is largely aimed at seeing whether a drug is safe and finding a tolerable dose.”

Editor’s note: This story is about a new melanoma drug called IMCgp100 that is being tested in patients. Learn more about immunotherapy drugs and clinical trials for melanoma here.